CNS Drugs

, Volume 15, Issue 6, pp 469–494 | Cite as

Smoking in Patients Receiving Psychotropic Medications

A Pharmacokinetic Perspective
Review Article


Many psychiatric patients smoke, and are believed to be heavier smokers than those without psychiatric disorders. Cigarette smoking is one of the environmental factors that contributes to interindividual variations in response to an administered drug. Polycyclic aromatic hydrocarbons (PAHs) present in cigarette smoke induce hepatic aryl hydrocarbon hydroxylases, thereby increasing metabolic clearance of drugs that are substrates for these enzymes. PAHs have been shown to induce 3 hepatic cytochrome P450 (CYP) isozymes, primarily CYP1A1, 1A2 and 2E1. Drug therapy can also be affected pharmacodynamically by nicotine.

The most common effect of smoking on drug disposition in humans is an increase in biotransformation rate, consistent with induction of drug-metabolising enzymes. Induction of hepatic enzymes has been shown to increase the metabolism and to decrease the plasma concentrations of imipramine, clomipramine, fluvoxamine and trazodone. The effect of smoking on the plasma concentrations of amitriptyline and nortriptyline is variable. Amfebutamone (bupropion) does not appear to be affected by cigarette smoking.

Smoking is associated with increased clearance of tiotixene, fluphenazine, haloperidol and olanzapine. Plasma concentrations of chlorpromazine and clozapine are reduced by cigarette smoking. Clinically, reduced drowsiness in smokers receiving chlorpromazine, and benzodiazepines, compared with non-smokers has been reported. Increased clearance of the benzodiazepines alprazolam, lorazepam, oxazepam, diazepam and demethyl-diazepam is found in cigarette smokers, whereas chlordiazepoxide does not appear to be affected by smoking. Carbamazepine appears to be minimally affected by cigarette smoke, perhaps because hepatic enzymes are already stimulated by its own autoinductive properties.

Cigarette smoking can affect the pharmacokinetic and pharmacodynamic properties of many psychotropic drugs. Clinicians should consider smoking as an important factor in the disposition of these drugs.


  1. 1.
    DeSimone EM, Scott DM. Nicotine and caffeine abuse. In: Koda-Kimble MA, Young LY, editors. Applied therapeutics: the clinical use of drugs. 5th ed. Vancouver: Applied Therapeutics, Inc; 1992: 85–113Google Scholar
  2. 2.
    Pantuck EJ, Kuntzman R, Conney AH. Decreased concentration of phenacetin in plasma of cigarette smokers. Science 1972; 175: 1248–50PubMedCrossRefGoogle Scholar
  3. 3.
    Chan L, Horn JR. Management of metabolic drug interactions. In: Carter B, Lake K, Raebel M, et al., editors. Pharmacotherapy self-assessment program, 3rd Ed, gastroenterology module. Kansas City, MO: American College of Clinical Pharmacy 1999: 85–108Google Scholar
  4. 4.
    Parkinson A. Biotransformation of xenobiotics. In: Klaassen CD, Doull J, Amdur MO, editors. Toxicology: the basic science of poisons. 5th ed. New York: McGraw-Hill; 1996: 113–86Google Scholar
  5. 5.
    Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414–23PubMedGoogle Scholar
  6. 6.
    Zevin S, Benowitz NL. Drug interactions with tobacco smoking. Clin Pharmacokinet 1999; 36(6): 425–38PubMedCrossRefGoogle Scholar
  7. 7.
    Pelkonen O, Mäenpää J, Taavitsainen P, et al. Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenbiotica 1998; 28(12): 1203–53CrossRefGoogle Scholar
  8. 8.
    Gonzalez FJ. Human cytochromes P450: problems and prospects. Trends Pharmacol Sci 1992; 13: 346–52PubMedCrossRefGoogle Scholar
  9. 9.
    Carrillo JA, Benitez J. CYP 1A2 activity, gender, smoking as variables influencing the toxicity of caffeine. Br J Clin Pharmacol 1996; 41: 605–8PubMedCrossRefGoogle Scholar
  10. 10.
    Sachse C, Brockmoller J, Baurer S, et al. Functional significance of a C → A polymorphism in intron I of the cytochrome P 450 1A2 gene tested with caffeine. Br J Clin Pharmacol 1999; 47: 445–9PubMedCrossRefGoogle Scholar
  11. 11.
    Okey AB. Enzyme induction in the cytochrome P450 system. Pharmacol Ther 1990; 45: 241–98PubMedCrossRefGoogle Scholar
  12. 12.
    Ereshefsky L, Tran-Johnson T, Davis CM, et al. Pharmacokinetic factors affecting antidepressant drug clearance and clinical effect: evaluation of doxepin and imipramine — new data and review. Clin Chem 1988; 34(5): 863–80PubMedGoogle Scholar
  13. 13.
    Jusko WJ. Influence of cigarette smoking on drug metabolism in man. Drug Metab Rev 1979; 9(2): 221–36PubMedCrossRefGoogle Scholar
  14. 14.
    Luczynska C, Wilson K. The significance of the effects of cigarette smoking on drug disposition. Methods Find Exp Clin Pharmacol 1983; 5(7): 479–87PubMedGoogle Scholar
  15. 15.
    Özdemir V, Fourie J, Busto U, et al. Pharmacokinetic changes in the elderly: do they contribute to drug abuse and dependence? Clin Pharmacokinet 1996; 31(5): 372–85PubMedCrossRefGoogle Scholar
  16. 16.
    Jann MW, Fidone GS, Hernandez JM, et al. Clinical implications of increased antipsychotic plasma concentrations upon anticonvulsant cessation. Psychiatry Res 1989; 28: 153–9PubMedCrossRefGoogle Scholar
  17. 17.
    Edge SC, Markowitz JS, DeVane CL. Clozapine drug-drug interactions: a review of the literature. Hum Psychopharmacol 1997; 12: 5–20CrossRefGoogle Scholar
  18. 18.
    McCarthy R. Seizure following smoking cessation in a clozapine responder. Pharmacopsychiatry 1994; 27: 210–1PubMedCrossRefGoogle Scholar
  19. 19.
    Hughes JR, Frances RJ. How to help psychiatric patients stop smoking. Psychiatr Serv 1995; 46(5): 435–6, 45PubMedGoogle Scholar
  20. 20.
    Wong E. Collaborative drug therapy management and smoking cessation. Hosp Pharm 1999; 34(11): 1295–303Google Scholar
  21. 21.
    Aitchinson KJ, Jordan BD, Sharma T. The relevance of ethnic influences on pharmacogenetics to the treatment of psychosis. Drug Metab Drug Interact 2000; 16(1): 15–38Google Scholar
  22. 22.
    Lasser K, Boyd JW, Woolhander S, et al. Smoking and mental illness. JAMA 2000; 284: 2606–10PubMedCrossRefGoogle Scholar
  23. 23.
    Ziegler VE, Biggs JT. Tricyclic plasma levels effects of age, race, sex, and smoking. JAMA 1977; 238(20): 2167–9PubMedCrossRefGoogle Scholar
  24. 24.
    Rickels K, Weise C, Case G, et al. Tricyclic plasma levels in depressed outpatients treated with amitriptyline. Psychopharmacology 1983; 80: 14–8PubMedCrossRefGoogle Scholar
  25. 25.
    Norman TR, Burrows GD, Maguire KP, et al. Cigarette smoking and plasma nortriptyline levels. Clin Pharmacol Therapeutics 1976; 21(4): 453–6Google Scholar
  26. 26.
    Linnoila M, George L, Guthrie S, et al. Effect of alcohol consumption and cigarette smoking on antidepressant levels of depressed patients. Am J Psychiatry 1981; 138(6): 841–2PubMedGoogle Scholar
  27. 27.
    Perry PJ, Browne JL, Prince RA, et al. Effects of smoking on nortriptyline plasma concentrations in depressed patients. Ther Drug Monit 1986; 8(3): 279–84PubMedCrossRefGoogle Scholar
  28. 28.
    Perel JM, Mendlewicz J, Shostak M, et al. Plasma levels of impramine in depression. Neuropsychobiology 1976; 2: 193–202PubMedCrossRefGoogle Scholar
  29. 29.
    John VA, Luscombe DK, Kemp H. Effects of age, cigarette smoking and the oral contraceptive on the pharmacokinetics clomipramine and its desmethyl metabolite during chronic dosing. J Int Med Res 1980; 8Suppl. 3: 88–95PubMedGoogle Scholar
  30. 30.
    Spigset O, Carleborg L, Hedenmalm K, et al. Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clin Pharmacol Ther 1995; 58(4): 399–403PubMedCrossRefGoogle Scholar
  31. 31.
    Ishida M, Otani K, Kaneko S, et al. Effects of various factors on steady-state plasma concentrations of trazodone and its active metabolite m-chlorphenylpiperazine. Int Clin Psychopharmacol 1995; 10: 143–6PubMedCrossRefGoogle Scholar
  32. 32.
    Hsyu P, Singh A, Giargiari TD, et al. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol 1997; 37: 737–43PubMedGoogle Scholar
  33. 33.
    Rigal JG, Albin H, Cuchier AR, et al. Imipramine blood levels and clinical outcome. J Clin Psychopharmacol 1987; 7: 222–9PubMedCrossRefGoogle Scholar
  34. 34.
    Miller LG. Cigarettes and drug therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharm 1990; 9: 125–35PubMedGoogle Scholar
  35. 35.
    Luscome DK, John V. Influence of age, cigarette smoking and oral contraceptive on plasma concentrations of clomipramine. Postgrad Med J 1980; 56Suppl. 1: 99–102Google Scholar
  36. 36.
    Gex-Fabry M, Balant-Gorgia AE, Balant LP, et al. Clomipramine metabolism model-based analysis of variability factors from drug monitoring data. Clin Pharmacokinet 1990; 19(3): 241–55PubMedCrossRefGoogle Scholar
  37. 37.
    Shimoda K, Noguchi T, Ozeki Y, et al. Metabolism of clomipramine in a Japanese psychiatric population: hydroxylation, desmethylation, and glucuronidation. Neuropsychopharmacology 1995; 12(4): 323–33PubMedCrossRefGoogle Scholar
  38. 38.
    Amchin J, Zarycranski W, Taylor KP, et al. Effect of venlafaxine on CYP1A2-dependent pharmacokinetics and metabolism of caffeine. J Clin Pharmacol 1999; 39: 252–9PubMedGoogle Scholar
  39. 39.
    Diwan A, Castine M, Pomerleau CS, et al. Differential prevalence of cigarette smoking in patients with schizophrenic vs mood disorders. Schizophr Res 1998; 33: 113–8PubMedCrossRefGoogle Scholar
  40. 40.
    Dalack GW, Meador-Woodruff JH. Smoking, smoking withdrawal and schizophrenia: case reports and a review of the literature. Schizophr Res 1996; 22: 133–41PubMedCrossRefGoogle Scholar
  41. 41.
    Nilsson A, Waller L, Rosengren A, et al. Cigarette smoking is associated with abnormal involuntary movements in the general male population — a study of men born in 1933. Biol Psychiatry 1997; 41: 717–23PubMedCrossRefGoogle Scholar
  42. 42.
    Vinarová E, Vinar O, Kalvach Z. Smoker need higher doses of neuroleptic drugs. Biol Psychiatry 1984; 19(8): 1265–8PubMedGoogle Scholar
  43. 43.
    Salokangas R, Saarijärvi S, Taiminen T, et al. Effect of smoking on neuroleptics in schizophrenia. Schizophr Res 1997; 23: 55–60PubMedCrossRefGoogle Scholar
  44. 44.
    Swett Jr C. Drowsiness due to chlorpromazine in relation to cigarette smoking. Arch Gen Psychiatry 1974; 31: 211–3PubMedCrossRefGoogle Scholar
  45. 45.
    Stimmel GL, Fallon I. Chlorpromazine plasma levels, adverse effects, and tobacco smoking: Case report. J Clin Psychiatry 1983; 44(11): 420–2PubMedGoogle Scholar
  46. 46.
    Pantuck EJ, Pantuck CB, Anderson KE, et al. Cigarette smoking and chlorpromazine disposition and actions. Clin Pharmacol Ther 1982; 31: 533–8PubMedCrossRefGoogle Scholar
  47. 47.
    Chetty M, Miller R, Moodley SV. Smoking and body weight influence the clearance of chlorpromazine. Eur J Clin Pharmacol 1994; 46: 523–6PubMedCrossRefGoogle Scholar
  48. 48.
    Ereshefsky L, Saklad SR, Watanabe MD, et al. Thiothixene pharmacokinetics interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variables. J Clin Psychopharmacol 1991; 11(5): 296–301PubMedCrossRefGoogle Scholar
  49. 49.
    Ereshefsky L, Jann MW, Saklad SR, et al. Effects of smoking on fluphenazine clearance in psychiatric inpatients. Biol Psychiatry 1985; 20: 329–52PubMedCrossRefGoogle Scholar
  50. 50.
    Jann MW, Saklad SR, Ereshefsky L, et al. Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance. Psychopharmacology 1986; 90: 468–70PubMedCrossRefGoogle Scholar
  51. 51.
    Miller DD, Kelly MW, Perry PJ, et al. The influence of cigarette smoking on haloperidol pharmacokinetics. Biol Psychiatry 1990; 28: 529–31PubMedCrossRefGoogle Scholar
  52. 52.
    Perry PJ, Miller DD, Arndt SV, et al. Haloperidol dosing requirements: the contribution of smoking and nonlinear pharmacokinetics. J Clin Psychopharmacol 1993; 13(1): 46–51PubMedCrossRefGoogle Scholar
  53. 53.
    Midha KK, Hawes EM, Hubbard JW, et al. A pharmacokinetic study of trifluoperazine in two ethnic populations. Psychopharmacology 1988; 95: 333–8PubMedCrossRefGoogle Scholar
  54. 54.
    Midha KK, Chakraborty BS, Ganes DA, et al. Intersubject variation in the pharmacokinetics of haloperidol and reduced haloperidol. J Clin Psychopharmacol 1989; 9(2): 98–104PubMedCrossRefGoogle Scholar
  55. 55.
    Dysken MW, Kim SW, Vatassery G, et al. Haloperidol decanoate pharmacokinetics in red blood cells and plasma. J Clin Psychopharmacol 1992; 12(2): 128–32PubMedCrossRefGoogle Scholar
  56. 56.
    Dahl ML, Llerena A, Bondesson U, et al. Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphism. Br J Clin Pharmacol 1994; 37: 71–4PubMedCrossRefGoogle Scholar
  57. 57.
    Callaghan JT, Bergstrom RF, Ptak LR, et al. Olanzapine pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999; 37(3): 177–93PubMedCrossRefGoogle Scholar
  58. 58.
    Kondo T, Tanaka O, Otani K, et al. Possible inhibitory effect of diazepam on the metabolism of zotepine, an antipsychotic drug. Psychopharmacology 1996; 127: 311–4PubMedGoogle Scholar
  59. 59.
    Haring C, Fleischhacker WW, Schett P, et al. Influence of patient-related variables on clozapine plasma levels. Am J Psychiatry 1990; 147(11): 1471–5PubMedGoogle Scholar
  60. 60.
    Hasegawa M, Gutierrez-Esteinou R, Way L, et al. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J Clin Psychopharmacol 1993; 13(6): 383–90PubMedCrossRefGoogle Scholar
  61. 61.
    Wetzel H, Anghelescu I, Szegedi A, et al. Pharmacokinetic interaction of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol 1998; 18(1): 2–9PubMedCrossRefGoogle Scholar
  62. 62.
    Jann MW, Grimsley SR, Gray EC, et al. Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 1993; 24: 161–76PubMedCrossRefGoogle Scholar
  63. 63.
    Kisicki JC, Bergsrom RF, Cerimele BJ, et al. Olanzapine: bioequivalence of capsule and tablet formulations. Lilly Laboratory for Clinical Research. Eli Lilly and Co., 1995 (Data on file)Google Scholar
  64. 64.
    Otani K, Kondo T, Kaneko S, et al. Steady-state serum kinetics of zotepine. Hum Psychopharmacol 1993; 7: 331–6CrossRefGoogle Scholar
  65. 65.
    Balant-Geogia AE, Gex-Fabry M, Genet C, et al. Therapeutic drug monitoring of risperidone using a new rapid HPLC method: reappraisal of interindividual variability factors. Ther Drug Monitor 1999; 21: 105–15CrossRefGoogle Scholar
  66. 66.
    Ochs HR, Greenblatt DJ, Burstein ES. Lack of influence of cigarette smoking on triazolam pharmacokinetics. Br J Clin Pharmacol 1987; 23: 759–63PubMedCrossRefGoogle Scholar
  67. 67.
    Otani K, Yasui N, Furukori H, et al. Relationship between single oral dose pharmacokinetics of alprazolam and triazolam. Int Clin Psychopharmacol 1997; 12: 153–7PubMedCrossRefGoogle Scholar
  68. 68.
    Hossain M, Wright E, Baweja R, et al. Nonlinear mixed effects modeling of single dose and multiple dose data for an immediate release (IR) and a controlled released (CR) dosage form of alprazolam. Pharm Res 1997; 14(3): 309–15PubMedCrossRefGoogle Scholar
  69. 69.
    Greenblatt DJ, Allen MD, Locniskar A, et al. Lorazepam kinetics in the elderly. Clin Pharmacol Ther 1979; 26(1): 103–13PubMedGoogle Scholar
  70. 70.
    Ochs HR, Greenblatt DJ, Knüchel M. Kinetics of diazepam, midazolam, and lorazepam in cigarette smokers. Chest 1985; 87(2): 223–6PubMedCrossRefGoogle Scholar
  71. 71.
    Greenblatt DJ, Allen MD, Locniskar A, et al. Diazepam disposition determinants. Clin Pharmacol Ther 1980; 27(3): 301–12PubMedCrossRefGoogle Scholar
  72. 72.
    Norman TR, Fulton A, Burrows GD, et al. Pharmacokinetics of N-desmethyldiazepam after a single oral dose of clorazepate: the effect of smoking. Clin Pharmacol 1981; 229–33Google Scholar
  73. 73.
    Ochs HR, Greenblatt DJ, Locniskar A, et al. Influence of propranolol coadministration on cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. Klin Wochenschr 1986; 64: 1217–21PubMedCrossRefGoogle Scholar
  74. 74.
    Desmond PV, Roberts PK, Wilkinson GR, et al. No effect of smoking on the metabolism of chlordiazepoxide. N Engl J Med 1979; 300: 199–200PubMedGoogle Scholar
  75. 75.
    Jick H, Slone D, Shapiro S, et al. Clinical depression of the central nervous system due to diazepam and chlordiazepoxide in the relation to cigarette smoking and age. N Engl J Med 1973; 288(6): 277–80CrossRefGoogle Scholar
  76. 76.
    Miller RR. Effects of smoking on drug action. Clin Pharmacol Ther 1977; 22(5): 749–56PubMedGoogle Scholar
  77. 77.
    Klotz U, Avant GR, Hoyumpa A, et al. The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest 1975; 55: 347–59PubMedCrossRefGoogle Scholar
  78. 78.
    Miller LG. Recent developments in the study of the effects of cigarette smoking on clinical pharmacokinetics and clinical pharmacodynamics. Clin Pharmacokinet 1989; 17(2): 90–108PubMedCrossRefGoogle Scholar
  79. 79.
    Cloyd JC, Remmel RP. Antiepileptic drug pharmacokinetics and interactions: impact on treatment of epilepsy. Pharmacotherapy 2000; 20 (8 Pt 2): 139S–51SPubMedCrossRefGoogle Scholar
  80. 80.
    Benetello P, Furlanut M, Pasqui L, et al. Absence of effect of cigarette smoking on serum concentrations of some anticonvulsants in epileptic patients. Clin Pharmacokinet 1987; 12(4): 302–4PubMedCrossRefGoogle Scholar
  81. 81.
    Martin ES, Crismon ML, Godley PJ. Postinduction carbamazepine clearance in an adult psychiatric population. Pharmacotherapy 1991; 11(4): 296–302PubMedGoogle Scholar
  82. 82.
    Ereshefsky L, Jann MW. Lithium. In: Mungall D, editor. Applied Clinical Pharmacokinetics. New York: Raven Press, 1983: 245–70Google Scholar
  83. 83.
    Henningfeld JE, Schuh LM, Jarvik ME. Pathophysiology of tobacco dependence. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995: 1715–29Google Scholar
  84. 84.
    Clarke PBS. Dopaminergic mechanisms in the locomotor stimulant effects of nicotine. Biochem Pharmacol 1990; 40: 1427–32PubMedCrossRefGoogle Scholar
  85. 85.
    Porchet HC, Benowitz NL, Sheiner LB, et al. Apparent tolerance to the acute effect of nicotine results in part from distribution kinetics. J Clin Invest 1987; 80: 1466–71PubMedCrossRefGoogle Scholar
  86. 86.
    Robinson DE, Balter NJ, Schwartz SL. A physiologically based pharmacokinetic model for nicotine and cotinine in man. J Pharmacokinet Biopharm 1992; 20: 591–609PubMedGoogle Scholar
  87. 87.
    Benowitz NL, Jacob P. Nicotine and cotinine elimination pharmacokinetics in smokers and nonsmokers. Clin Pharmacol Ther 1993; 53: 316–23PubMedCrossRefGoogle Scholar
  88. 88.
    Emerich DF, Zanol MD, Norman AB, et al. Nicotine potentiates haloperidol induced catalepsy and locomotor hypoactivity. Pharmacol Biochem Behav 1991; 38: 875–80PubMedCrossRefGoogle Scholar
  89. 89.
    McConville BJ, Folgelson MH, Norman AB, et al. Nicotine potentiation of haloperidol in reducing tic frequency in Tourette’s disorder. Am J Psychiatry 1991; 148: 793–4PubMedGoogle Scholar
  90. 90.
    Binder RL, Kazamatsuri H, Nishimura T, et al. Smoking and tardive dyskinesia. Biol Psychiatry 1987; 22: 1280–2PubMedCrossRefGoogle Scholar
  91. 91.
    Kirch DG, Alho AM, Wyatt RJ. Hypothesis: a nicotine-dopamine interaction linking smoking with Parkinson’s disease and tardive dyskinesia. Cell Mol Neurobiol 1988; 8: 285–91PubMedCrossRefGoogle Scholar
  92. 92.
    Menza MA, Grossman N, VanHorn M, et al. Smoking and movement disorders in psychiatric patients. Biol Psychiatry 1991; 30: 109–15PubMedCrossRefGoogle Scholar
  93. 93.
    Basile VS, Ozdemir V, Masellis M, et al. A functional polymorphism of the cytochrome P450 1A2 gene: association with tardive dyskinesia in schizophrenia. Mol Psychiatry 2000; 5: 410–7PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  • Hiral D. Desai
    • 1
  • Julia Seabolt
    • 2
  • Michael W. Jann
    • 1
  1. 1.Department of Pharmacy Practice and Pharmaceutical SciencesMercer University, Southern School of PharmacyAtlantaUSA
  2. 2.College of Pharmacy and Department of PsychiatryUniversity of Illinois at ChicagoChicagoUSA

Personalised recommendations